Equities research analysts expect bluebird bio, Inc. (NASDAQ:BLUE) to report earnings per share (EPS) of ($1.64) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for bluebird bio’s earnings. The highest EPS estimate is ($0.78) and the lowest is ($2.10). bluebird bio reported earnings of ($1.88) per share during the same quarter last year, which would indicate a positive year over year growth rate of 12.8%. The company is scheduled to report its next earnings results on Wednesday, February 28th.
According to Zacks, analysts expect that bluebird bio will report full-year earnings of ($6.72) per share for the current fiscal year, with EPS estimates ranging from ($7.27) to ($5.44). For the next year, analysts anticipate that the firm will post earnings of ($6.85) per share, with EPS estimates ranging from ($7.85) to ($3.53). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for bluebird bio.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same quarter in the prior year, the firm posted ($2.07) earnings per share. The business’s revenue was up 397.4% on a year-over-year basis.
A number of analysts have recently weighed in on BLUE shares. Wedbush restated an “outperform” rating and issued a $174.00 target price (up from $135.00) on shares of bluebird bio in a report on Thursday, November 2nd. Cantor Fitzgerald restated a “sell” rating and issued a $39.00 target price on shares of bluebird bio in a report on Thursday, September 28th. Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a report on Monday, October 16th. BMO Capital Markets boosted their target price on shares of bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a report on Monday, October 30th. Finally, Goldman Sachs Group restated a “buy” rating and issued a $186.00 target price on shares of bluebird bio in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the stock. bluebird bio presently has a consensus rating of “Hold” and an average target price of $157.45.
Shares of bluebird bio (NASDAQ:BLUE) opened at $179.90 on Thursday. bluebird bio has a fifty-two week low of $60.95 and a fifty-two week high of $222.03. The firm has a market cap of $8,300.00, a PE ratio of -25.66 and a beta of 2.08.
In other bluebird bio news, insider David Davidson sold 4,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $131.31, for a total value of $525,240.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Nick Leschly sold 117,500 shares of the business’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the completion of the sale, the insider now directly owns 293,232 shares of the company’s stock, valued at $53,978,146.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 215,082 shares of company stock valued at $37,227,332. 3.90% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. QS Investors LLC raised its holdings in shares of bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 500 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of bluebird bio by 454.2% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 813 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares in the last quarter. Biondo Investment Advisors LLC bought a new stake in shares of bluebird bio in the 3rd quarter valued at about $203,000. Finally, SG Americas Securities LLC raised its stake in shares of bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 295 shares in the last quarter.
TRADEMARK VIOLATION WARNING: “-$1.64 Earnings Per Share Expected for bluebird bio, Inc. (BLUE) This Quarter” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/12/1-64-earnings-per-share-expected-for-bluebird-bio-inc-blue-this-quarter.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Get a free copy of the Zacks research report on bluebird bio (BLUE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.